Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Avicidin advances to phase II

March 5, 1998

DiagnoCure signs agreements related to development of targeted nanoerythrosomes

March 4, 1998

Phase I/II trial results reported for OncoVax-P formulated with JenVax-100a

March 3, 1998

IDEC-Y2B8/rituximab combination enters phase III

Feb. 27, 1998

UCSF receives green light to develop new breast cancer therapy

Feb. 24, 1998

Maxamine progresses to phase III in AML

Feb. 23, 1998

Phase I trial results of DAB389IL-2 in lymphoma

Feb. 20, 1998

Seragen fusion toxin will get priority review

Feb. 5, 1998

Anti-ErbB3 antibodies described by Genentech in patent literature

Feb. 3, 1998

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...